Top Considerations in Pediatric Cancer Treatment: What Payers Should KnowA Stanford expert describes ideal treatment locations, common barriers, and how payers could better support patients and families.
What oncologists say about new cancer treatment optionsA new report from Cardinal Health Specialty Solutions gives behind-the-scenes perspectives from oncologists about CAR-T cell therapies, biosimilars and AML therapies (or genomic medicines)
Genetic testing in oncology: 5 things payers should knowAs genomics continues to evolve, here are five things to know about genetic testing and counseling.
Payments to specialists could yo-yo under MIPSAvalere conducted an analysis to assess the effect of MIPS. Here are the surprising results.
Four ways the genomic data commons will advance cancer careA new cancer database, the Genomic Data Commons, aims to make research more accessible
Proposed Medicare Part B rule would cut payments for some drugsNew analysis finds proposed Medicare payment changes for physician-administered drugs would reduce reimbursement for those that cost more than $480 per day in 2016. Seven of the 10 drugs that constitute the largest reduction in reimbursement are used to treat cancer.
Are we ready to assess the value of cancer drugs?A presenter at the AMCP Annual Meeting examines two different tools released by ASCO and NCCN and how a managed care organization utilizes these tools in the formulary review process.
Value-based treatments, discoveries address top cancers
Achieving balance: Providing high-value cancer care
Achieving balance: Providing high-value cancer careHow plans can achieve the right balance between cost and outcomes
Oncologists not prescribing expensive cancer drugsIn the latest controversy over the high cost of certain prescription medications, a recent Reuters article said that more oncologists won’t prescribe expensive drugs.